AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A compound of formula (Ia) or (Ib):



(Ia)

, or



(Ib)

,

or a pharmaceutically acceptable salt, ~~prodrug~~, hydrate, tautomer or solvate thereof, wherein:

X is O or S;

R^1 is selected from the group consisting of









and

where R^{2a} is independently selected from the group consisting of: $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_5\text{-}C_{10})$aryl, $(C_1\text{-}C_6)$alkylaryl, amino, carbonyl, carboxyl, $(C_2\text{-}C_6)$acid, $(C_1\text{-}C_6)$ester, $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclyl, $(C_1\text{-}C_6)$alkoxy, nitro, halo, hydroxyl, $(C_1\text{-}C_6)$alkoxy$(C_1\text{-}C_6)$ester, and where alkyl, alkenyl, alkynyl, cycloalkyl, aryl, amino, acid, ester, heteroaryl, heterocyclyl, and alkoxy of R^{2a} is optionally substituted by at least one moiety independently selected from the group consisting of halo, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, phenyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclic, formyl, NC-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-,

$((C_1\text{-}C_6)alkyl)_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[$((C_1\text{-}C_6)alkyl)$-N]-(C=O)-, O_2N-, amino, $(C_1\text{-}C_6)$alkylamino, $((C_1\text{-}C_6)alkyl)_2$-amino, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-(C=O)-[$((C_1\text{-}C_6)alkyl)$-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[$((C_1\text{-}C_6)alkyl)$-N]-, H_2N-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-HN-(C=O)-NH-, $((C_1\text{-}C_6)alkyl)_2N$-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-HN-(C=O)-[($(C_1\text{-}C_6)$alkyl)-N]-, $((C_1\text{-}C_6)alkyl)_2N$-(C=O)-[$(C_1\text{-}C_6)$alkyl-N]-, phenyl-HN-(C=O)-NH-, $(phenyl)_2N$-(C=O)-NH-, phenyl-HN-(C=O)-[$((C_1\text{-}C_6)alkyl)$-N]-, $(phenyl\text{-})_2N$-(C=O)-[($(C_1\text{-}C_6)$alkyl)-N]-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-[($(C_1\text{-}C_6)$alkyl)-N]-, phenyl-O-(C=O)-NH-, phenyl-O-(C=O)-[(alkyl)-N]-, $(C_1\text{-}C_6)$alkyl-SO_2NH-, phenyl-SO_2NH-, $(C_1\text{-}C_6)$alkyl-SO_2-, phenyl-SO_2-, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, phenoxy, $(C_1\text{-}C_6)$alkyl-(C=O)-O-, $(C_1\text{-}C_6)$ester-$(C_1\text{-}C_6)$alkyl-O-, phenyl-(C=O)-O-, H_2N-(C=O)-O-, $(C_1\text{-}C_6)$alkyl-HN-(C=O)-O-, $((C_1\text{-}C_6)alkyl)_2N$-(C=O)-O-, phenyl-HN-(C=O)-O-, and $(phenyl)_2N$-(C=O)-O-; ~~a saturated, unsaturated, or aromatic C_3-C_{20} mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S~~, wherein R^1 can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo$(C_1\text{-}C_6)$alkyl, perhalo$(C_1\text{-}C_6)$alkyl, perhalo$(C_1\text{-}C_6)$alkoxy, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, hydroxy, oxo, mercapto, $(C_1\text{-}C_6)$alkylthio, $(C_1\text{-}C_6)$alkoxy, $(C_5\text{-}C_{10})$aryl or $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$aryloxy or $(C_5\text{-}C_{10})$heteroaryloxy, $(C_5\text{-}C_{10})$ar$(C_1\text{-}C_6)$alkyl or $(C_5\text{-}C_{10})$heteroar$(C_1\text{-}C_6)$alkyl, $(C_5\text{-}C_{10})$ar$(C_1\text{-}C_6)$alkoxy or $(C_5\text{-}C_{10})$heteroar$(C_1\text{-}C_6)$alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkylamino$(C_1\text{-}C_6)$alkyl, di$(C_1\text{-}C_6)$alkylamino$(C_1\text{-}C_6)$alkyl, $(C_5\text{-}C_{10})$heterocyclyl$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl- and di$(C_1\text{-}C_6)$alkylamino, cyano, nitro, carbamoyl, $(C_1\text{-}C_6)$alkylcarbonyl, $(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_6)$alkylaminocarbonyl, di$(C_1\text{-}C_6)$alkylaminocarbonyl, $(C_5\text{-}C_{10})$arylcarbonyl, $(C_5\text{-}C_{10})$aryloxycarbonyl, $(C_1\text{-}C_6)$alkylsulfonyl, and $(C_5\text{-}C_{10})$arylsulfonyl;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, phenyl, $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclic, $(C_3\text{-}C_{10})$cycloalkyl, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, phenoxy, $(C_5\text{-}C_{10})$heteroaryl-O-, $(C_5\text{-}C_{10})$heterocyclic-O-, $(C_3\text{-}C_{10})$cycloalkyl-O-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-SO_2-, $(C_1\text{-}C_6)$alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1\text{-}6}HN$-, $(C_1\text{-}C_6)$alkyl HN-, $(C_1\text{-}C_6)$alkylamino, $[(C_1\text{-}C_6)alkyl]_2$-amino, $(C_1\text{-}C_6)$alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-,

$(C_1\text{-}C_6)$alkyl-(C=O)-[(($(C_1\text{-}C_6)$alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[($(C_1\text{-}C_6)$alkyl)-N]-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, H_2N(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(($C_1\text{-}C_6$)alkyl)-N]-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)- and $(C_1\text{-}C_6)$alkyl-(C=O)-O-,

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^3 is optionally substituted by at least one substituent independently selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, halo$(C_1\text{-}C_6)$alkyl, halo, H_2N-, $Ph(CH_2)_{1\text{-}6}HN$-, and $(C_1\text{-}C_6)$alkylHN-;

s is an integer from one to five;

R^4 is independently selected from the group consisting of: hydrogen, halo, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, phenyl, $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclic, $(C_3\text{-}C_{10})$cycloalkyl, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, phenoxy, $(C_5\text{-}C_{10})$heteroaryl-O-, $(C_5\text{-}C_{10})$heterocyclic-O-, $(C_3\text{-}C_{10})$cycloalkyl-O-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-SO_2-, $(C_1\text{-}C_6)$alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1\text{-}6}HN$-, $(C_1\text{-}C_6)$alkylHN-, $(C_1\text{-}C_6)$alkylamino, $[(C_1\text{-}C_6)\text{alkyl}]_2$-amino, $(C_1\text{-}C_6)$alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-(C=O)-(($C_1\text{-}C_6$)alkyl)-N-, phenyl-(C=O)-NH-, phenyl-(C=O)-(($C_1\text{-}C_6$)alkyl)-N]-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, H_2N(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, (($C_1\text{-}C_6$)alkyl)$_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-(($C_1\text{-}C_6$)alkyl)-N]-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)- and $(C_1\text{-}C_6)$alkyl-(C=O)-O-,

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^4 is optionally substituted by at least one substituent independently selected from the group consisting of $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, halo$(C_1\text{-}C_6)$alkyl, halo, H_2N-, Ph $(CH_2)_{1\text{-}6}HN$-, $(C_1\text{-}C_6)$alkylHN-, $(C_5\text{-}C_{10})$heteroaryl and $(C_5\text{-}C_{10})$heterocyclyl;

with the proviso that when R^4 is a substituted phenyl moiety, then (a) R^1 is not naphthyl, phenyl or anthracenyl and (b) if R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms

independently selected from N, O and S, then the fused cyclic ring of said R^1 moiety is substituted;

with the proviso that when R^4 is NH_2 and X is S, then R^1 is not an amino-substituted pyridyl or pyrimidinyl moiety; and

with the provisio that when in formula (Ia) R^4 is CH_3 and X is S, R^1 is not a 3, 4-dimethoxy substituted phenyl moiety.

2. (ORIGINAL) A compound of claim 1, wherein R^1 is



3. (ORIGINAL) A compound of claim 1, wherein R^1 is



4. (ORIGINAL) A compound of claim 1, wherein R^1 is



5. (ORIGINAL) A compound of claim 1, wherein R^1 is



6. (ORIGINAL) A compound of claim 1, wherein R^1 is



7. (ORIGINAL) A compound of claim 1, wherein R^1 is



8. (ORIGINAL) A compound of claim 1, wherein R^1 is



or

9. (ORIGINAL) A compound of claim 1, wherein X is O; s is one to two; R^3 is hydrogen or $(C_1$-$C_6)$alkyl; and R^4 is H, $(C_1$-$C_6)$alkyl, or amino.

10. (ORIGINAL) A compound of claim 1, wherein X is S; s is one to two; R^3 is hydrogen or $(C_1$-$C_6)$alkyl; and R^4 is H, $(C_1$-$C_6)$alkyl, or amino.

11. (CURRENTLY AMENDED) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

12. (CURRENTLY AMENDED) A method of treating a TGF-related disease state in an animal or human comprising the step of administering a therapeutically effective amount of a compound of claim 1 to the animal or human suffering from the TGF-related disease state selected from the group consisting of ~~cancer~~, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.

13. (CANCELED)

14. (NEW) A compound selected from the groups consisting of ;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-methyl-pyridine;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-pyridine;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-methoxy-pyridine;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-trifluoromethyl-pyridine;

2-Methyl-5-[4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-2H-benzotriazole;

4-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;

1-Methyl-6-[4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-1H-benzotriazole;

6-(4-Pyridin-2-yl-oxazol-5-yl)-quinoxaline;

6-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-quinoxaline;

6-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;

6-(4-pyridin-2-yl-oxazol-5-yl)-quinoline;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-ethyl-pyridine;

2-(5-Benzo[1,3]dioxol-5-yl-oxazol-4-yl)-6-propyl-pyridine;

6-[4-(6-Methyl-pyridin-2-yl)-oxazol-5-yl]-benzothiazole;

2-(4-Benzo[1,3]dioxol-5-yl-oxazol-5-yl)-6-methyl-pyridine;

4-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;

1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-1H-benzotriazole;

2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-2H-benzotriazole;

6-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;

6-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-quinoxaline;

2-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-[1,5]naphthyridine;

{4-[5-(6-Methyl-pyridin-2-yl)-oxazol-4-yl]-pyridin-2-yl}-phenyl-amine;

2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-oxazol-5-yl)-6-methyl-pyridine;

1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-1H-benzotriazole;

2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-2H-benzotriazole;

6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;

6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoxaline;

2-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-[1,5]naphthyridine;

{4-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-pyridin-2-yl}-phenyl-amine;

4-[2-Methyl-5-(6-methyl-pyridin-2-yl)-oxazol-4-yl]-quinoline;

4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

4-(3-Methyl-3H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

4-(2-Methyl-2H-benzotriazol-5-yl)-5-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

5-(6-Methyl-pyridin-2-yl)-4-quinolin-6-yl-thiazol-2-ylamine;

5-(6-Methyl-pyridin-2-yl)-4-quinoxalin-6-yl-thiazol-2-ylamine;

5-(6-Methyl-pyridin-2-yl)-4-[1,5]naphthyridin-2-yl-thiazol-2-ylamine;

{4-[2-Amino-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phenyl-amine;

5-(6-Methyl-pyridin-2-yl)-4-quinolin-4-yl-thiazol-2-ylamine;

4-(6-Methyl-pyridin-2-yl)-5-quinolin-6-yl-thiazol-2-ylamine;

5-(3-Methyl-3H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

5-(2-Methyl-2H-benzotriazol-5-yl)-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

5-Benzo[1,3]dioxol-5-yl-4-(6-methyl-pyridin-2-yl)-thiazol-2-ylamine;

4-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-yl-thiazol-2-ylamine;

4-(6-Methyl-pyridin-2-yl)-5-[1,5]naphthyridin-2-yl-thiazol-2-ylamine;

{4-[2-Amino-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-pyridin-2-yl}-phenyl-amine;

4-(6-Methyl-pyridin-2-yl)-5-quinolin-4-yl-thiazol-2-ylamine;

6-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;

1-Methyl-6-[2-methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-1H-benzotriazole;

2-Methyl-5-[2-methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-2H-benzotriazole;

2-(5-Benzo[1,3]dioxol-5-yl-2-methyl-oxazol-4-yl)-6-methyl-pyridine;

6-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-quinoxaline;

2-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-[1,5]naphthyridine;

{4-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-pyridin-2-yl}-phenyl-amine;

4-[2-Methyl-4-(6-methyl-pyridin-2-yl)-oxazol-5-yl]-quinoline;

1-Methyl-6-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;

2-Methyl-5-[4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;

2-(5-Benzo[1,3]dioxol-5-yl-thiazol-4-yl)-6-methyl-pyridine;

6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;

2-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;

{4-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-pyridin-2-yl}-phenyl-amine;

4-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;

6-[4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;

1-Methyl-6-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;

2-Methyl-5-[5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;

2-(4-Benzo[1,3]dioxol-5-yl-thiazol-5-yl)-6-methyl-pyridine;

6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;

2-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;

{4-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phenyl-amine;

4-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;

6-[5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline;

1-Methyl-6-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-1H-benzotriazole;

2-Methyl-5-[2-methyl-4-(6-methyl-pyridin-2-yl)-thiazol-5-yl]-2H-benzotriazole;

2-(5-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-4-yl)-6-methyl- pyridine;

6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoxaline;

2-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-[1,5]naphthyridine;

{4-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-pyridin-2-yl}-phenyl-amine;

4-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;

6-[2-methyl-4-(6-Methyl-pyridin-2-yl)-thiazol-5-yl]-quinoline;

1-Methyl-6-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-1H-benzotriazole;

2-Methyl-5-[2-methyl-5-(6-methyl-pyridin-2-yl)-thiazol-4-yl]-2H-benzotriazole;

2-(4-Benzo[1,3]dioxol-5-yl-2-methyl-thiazol-5-yl)-6-methyl-pyridine;

6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoxaline;

2-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-[1,5]naphthyridine;

{4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-pyridin-2-yl}-phenyl-amine;

4-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline and

6-[2-methyl-5-(6-Methyl-pyridin-2-yl)-thiazol-4-yl]-quinoline; or a pharmaceutically acceptable salt thereof.

15. (NEW) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 14 and a pharmaceutically acceptable carrier.